Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy

Acta Oncologica

Volumn 35, Issue 6, 1996, Pages 733-736

  Blom, René ^a   Palm, Niklas ^a   Simonsen, Ernst ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DOSIMETRY; DRUG THERAPY; PHYSIOLOGY; RADIOTHERAPY;

OVARIAN CARCINOMA; PACLITAXEL MONOTHERAPY; PLATINUM BASED CHEMOTHERAPY;

ONCOLOGY;

CIMETIDINE; CISPLATIN; CLEMASTINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0029860725     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609084007     Document Type: Article

References (17)

1. Gruppo Interregionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclofosfamid/cisplatin and with cyclofosfamid/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; 2: 353-9.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-68.
3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational/antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-59.
4. Donehower RC, Rowinsky EK. An overview of experience with Taxol (paclitaxel) in the USA. Cancer Treatment Reviews 1993; 19(Suppl. C): 63-78.
5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979; 277: 665-7.
6. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981; 256: 10435-41.
7. Caldas C, McGuire III WP. Paclitaxel (TAXOL) therapy in ovarian carcinoma. Semin Oncol 1993; 20: 50-5.
8. McGuire WP, Rowinsky EK, Rosenhein NB, et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
9. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynecologic oncology group study. J Clin Oncol 1994; 12: 1748-53.
10. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53.
11. Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666-71.
12. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense Taxol: High response rate in patients with platinum-resistent recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
13. Cannistra SA. Paclitaxel in ovarian cancer: How can we make it better? J Clin Oncol 1994; 12: 1743-4.
14. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
15. Ozols RF. USA update on paclitaxel in ovarian cancer. Ann Med 1995; 27: 00-00.
16. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
17. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.